vTv Therapeutics Randomizes First Participant in Phase 2a Cadisegliatin Study for Type 1 Diabetes

• vTv Therapeutics randomized the first participant in its Phase 2a Hybrid CATT1 pilot study of cadisegliatin in people with type 1 diabetes.
• The study evaluates the investigational oral therapy alongside insulin in patients using hybrid closed-loop insulin delivery systems.
• Results are intended to guide future Phase 3 research into glycemic control and hypoglycemia in this population.
• Enrollment in the separate Phase 3 CATT1 study, limited to insulin pen or open-loop pump users, was completed earlier this month.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270800PRIMZONEFULLFEED9853315) on October 27, 2026, and is solely responsible for the information contained therein.